Literature DB >> 3683459

The course and prognosis of different forms of chronic airways obstruction in a sample from the general population.

B Burrows1, J W Bloom, G A Traver, M G Cline.   

Abstract

We examined the course and prognosis in subjects selected from the general population who had chronic airflow obstruction at the time of their enrollment in a longitudinal epidemiologic study. Mortality and the rate of change in lung function were analyzed in relation to the initial clinical characteristics of the subjects. Twenty-seven subjects with symptoms and signs of asthma (Group I) had a higher survival rate and a much lower rate of decline in pulmonary function than the 45 subjects in Group III, whose clinical characteristics were more compatible with an emphysematous form of chronic obstructive pulmonary disease (COPD). The 10-year mortality among subjects in Group III (non-atopic smokers without a history of asthma) was close to 60 percent, whereas it was only 15 percent in Group I (atopic subjects or nonsmokers with known asthma). The mean overall rate of decline in forced expiratory volume in one second was 70 ml per year in Group III but less than 5 ml per year in Group I. Forty-five patients (Group II) who did not clearly fit into either Group I or III had intermediate values for survival and decline in pulmonary function. Previous data on mortality from COPD and the rate of progression of the condition, although compatible with our findings in patients who had an emphysematous form of disease, are not applicable to those with an asthmatic-bronchitic form. Better control of the progression of asthmatic bronchitis with therapy may explain its more favorable prognosis.

Entities:  

Mesh:

Year:  1987        PMID: 3683459     DOI: 10.1056/NEJM198711193172103

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  65 in total

Review 1.  Lung transplantation for chronic obstructive pulmonary disease: an exercise in quality rather than quantity?

Authors:  P A Corris
Journal:  Thorax       Date:  1999-08       Impact factor: 9.139

Review 2.  Airway hyperresponsiveness and COPD mortality.

Authors:  J Vestbo; E F Hansen
Journal:  Thorax       Date:  2001-09       Impact factor: 9.139

Review 3.  Chronic airway disease: the infection connection.

Authors:  S B Greenberg; R L Atmar
Journal:  Trans Am Clin Climatol Assoc       Date:  1999

4.  Exercise performance after standard rehabilitation in COPD patients with lung hyperinflation.

Authors:  Ernesto Crisafulli; Elena Venturelli; Gianluca Biscione; Guido Vagheggini; Andrea Iattoni; Sasha Lucic; Nicolino Ambrosino; Franco Pasqua; Alfredo Cesario; Enrico Maria Clini
Journal:  Intern Emerg Med       Date:  2011-11-22       Impact factor: 3.397

5.  Gender and chronic obstructive pulmonary disease: why it matters.

Authors:  Meilan K Han; Dirkje Postma; David M Mannino; Nicholas D Giardino; Sonia Buist; Jeffrey L Curtis; Fernando J Martinez
Journal:  Am J Respir Crit Care Med       Date:  2007-08-02       Impact factor: 21.405

6.  Bronchodilator treatment in asthma: continuous or on demand?

Authors:  A Lawton; M T Lopez-Vidriero
Journal:  BMJ       Date:  1992-02-22

7.  Inhaled corticosteroids and decline of lung function in community residents with asthma.

Authors:  P Lange; H Scharling; C S Ulrik; J Vestbo
Journal:  Thorax       Date:  2006-02       Impact factor: 9.139

8.  Irreversible airway obstruction in asthma.

Authors:  Louis-Philippe Boulet
Journal:  Curr Allergy Asthma Rep       Date:  2009-03       Impact factor: 4.806

9.  Lung Function Trajectories Leading to Chronic Obstructive Pulmonary Disease as Predictors of Exacerbations and Mortality.

Authors:  Jacob Louis Marott; Truls Sylvan Ingebrigtsen; Yunus Çolak; Jørgen Vestbo; Peter Lange
Journal:  Am J Respir Crit Care Med       Date:  2020-07-15       Impact factor: 21.405

Review 10.  Natural history of emphysema.

Authors:  Omar A Minai; Joshua Benditt; Fernando J Martinez
Journal:  Proc Am Thorac Soc       Date:  2008-05-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.